Loading...
OTCM
ARTHQ
Market cap0kUSD
Dec 30, Last price  
0.00USD
Name

Arch Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:ARTHQ chart
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
32.12%
Rev. gr., 5y
%
Revenues
76k
+383.80%
000000000011,56515,65275,724
Net income
-7m
L+63.31%
-5,037-36,611-1,853,791-8,142,823-2,947,526-5,992,370-7,788,856-4,814,032-2,723,407-4,012,106-6,569,242-4,275,854-6,982,836
CFO
-3m
L-24.28%
-2,136-33,757-1,336,332-3,348,502-4,239,386-4,747,027-5,616,248-5,913,563-5,268,302-5,044,755-5,958,628-4,456,075-3,374,216

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
IPO date
Jun 27, 2012
Employees
8
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT